Join
Live feed
·
PRReleasevia Quantisnow
Xilio Therapeutics Inc. logo

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors

ByQuantisnow·Wall Street's wire, on your screen.
XLO· Xilio Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track XLO (Xilio Therapeutics Inc.) and more on Quantisnow.